☆ 4.6 Article

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China

Guangjian Yang et al.

Summary: First-line chemotherapy plus angiogenesis inhibitors may provide better survival benefits for NSCLC patients with EGFR exon 20 insertions, while chemotherapy in combination with ICI may not achieve better survival benefits for this subset of patients. Activation of PI3K/AKT signaling may mediate intrinsic immunosuppression in NSCLC with EGFR exon 20 insertions.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC

Sai-Hong Ignatius Ou et al.

Summary: This study analyzed the spectrum of EGFR exon 20 insertion variants and the ability of PCR kits to detect these alterations in a large patient population from clinical trials and real-world cohorts. The results showed that PCR tests had limited ability to detect EGFR exon 20 insertion mutations, and NGS-based genetic testing is preferable.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets

Santiago Viteri et al.

Summary: This study analyzed real-world datasets to determine the frequency of EGFR exon 20 insertion mutations and compare the ability of PCR and NGS to identify them. The results showed that PCR-based assays have limited ability to identify EGFR exon 20 insertions, with approximately 50% of these mutations potentially being missed. NGS platforms are more appropriate for identifying patients who may benefit from targeted therapies for EGFR exon 20 insertions.

MOLECULAR ONCOLOGY (2023)

Add to Collection

Article Oncology

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Changlong He et al.

Summary: By comparing the detection rate and type of EGFR gene mutations in NSCLC samples using ARMS-PCR and NGS technologies, the study found significant differences in total mutation rate and mutation rates in different exons between the two methods. NGS technology has the potential to guide drug use for resistant patients, but further research is needed on the unknown significance of rare loci detected by NGS.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Jiabao Hou et al.

Summary: Platinum-based chemotherapy used to be the first choice for lung cancer, but EGFR tyrosine kinase inhibitors (TKIs) have become preferred treatment for NSCLC patients with EGFR gene mutations. However, patients with EGFR exon 20 insertion (ex20ins) mutations have poor prognosis and are insensitive to EGFR-TKIs. Recent clinical research has focused on developing therapies specifically targeting ex20ins mutations.

BIOMARKER RESEARCH (2022)

Add to Collection

Article Multidisciplinary Sciences

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer

Chia- Shen et al.

Summary: Detection of driver gene mutations is crucial in advanced NSCLC. The cobas EGFR mutation test has limitations due to its primer design, while next-generation sequencing-based assay provides a higher mutation detection coverage. Comprehensive genomic profiling can identify EGFR mutations missed by the cobas test and offers significant benefits to patients with NSCLC.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Oncology

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Sabine Zoechbauer-Mueller et al.

Summary: This study describes a rare case of a lung adenocarcinoma patient with an EGFR exon 20 insertion who has been treated with afatinib for 4.5 years, demonstrating potential efficacy of afatinib for this rare mutation. While two other rare EGFR mutation cases were reported, one patient did not experience long-term benefit due to disease progression.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations

Lyudmila Bazhenova et al.

Summary: Patients with EGFR exon20ins mutations in advanced NSCLC have poor prognosis and limited benefit from EGFR TKI treatment. More effective therapies are needed for this difficult-to-treat population.

LUNG CANCER (2021)

Add to Collection

Article Oncology

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

M. Kirchner et al.

Summary: The study found significantly lower levels of cytotoxic cells in EGFR-mutated tumors regardless of the affected exon, and significantly lower levels of Th1 cells in EGFR-Ex20mut tumors compared to EGFR/ERBB2wt tumors. Tumors with ERBB2 and EGFR Ex20 insertions exhibited significant immune reactivity and specific immunosuppressive characteristics, suggesting further evaluation of immune-modulators as partners to immune checkpoint inhibitors.

ESMO OPEN (2021)

Add to Collection

Meeting Abstract Oncology

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

Sai-Hong Ignatius Ou et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Chie Morita et al.

Summary: Patients with Exon20ins mutations and major mutations had similar clinical characteristics, but Exon20ins patients had less satisfactory clinical outcomes compared to M-mut patients.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

B. van Veggel et al.

LUNG CANCER (2020)

Add to Collection

Article Oncology

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

Guangjian Yang et al.

LUNG CANCER (2020)

Add to Collection

Review Oncology

EGFR exon 20 insertion mutations in non-small cell lung cancer

Fenfang Wang et al.

TRANSLATIONAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

Wenfeng Fang et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Seonggyu Byeon et al.

CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Review Oncology

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy

Lais Osmani et al.

SEMINARS IN CANCER BIOLOGY (2018)

Add to Collection

Article Oncology

Afatinib for an EGFR exon 20 insertionmutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival

Raymond Tsz-Tong Chan

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Uncommon EGFR mutations in advanced non-small cell lung cancer

Grainne M. O'Kane et al.

LUNG CANCER (2017)

Add to Collection

Article Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James C-H Yang et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

M. Beau-Faller et al.

ANNALS OF ONCOLOGY (2014)

Add to Collection

Article Oncology

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Geoffrey R. Oxnard et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

Add to Collection

Article Cell Biology

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Hiroyuki Yasuda et al.

SCIENCE TRANSLATIONAL MEDICINE (2013)

Add to Collection

Review Oncology

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Helena Linardou et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.